Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc. (CGTX) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · CGTX · as of Sep 30, 2025
Ownership Breakdown
69
Institutional Holders
▲ 21 vs Q2
$28.72M
Total Inst. Value
▲ $25.21M vs Q2
73.58M
Shares Outstanding
freeFloat 80.37%
21.27M
13F Shares Held
▲ 10.03M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
CGTX largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BIOS CAPITAL MANAGEMENT, LP biological products, (no diagnostic substances) | 6.00M | 9.42% | 9.42% | $8.10B | Nov 12, 2025 | — held |
DAVENPORT & CO LLC biological products, (no diagnostic substances) | 2.69M | 4.22% | 4.22% | $3.63B | Oct 15, 2025 | NEW |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 2.68M | 4.21% | 4.21% | $3.62B | Nov 7, 2025 | ▲ 1.38M |
TANG CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 1.20M | 1.88% | 1.88% | $1.62B | Nov 14, 2025 | NEW |
CHESCAPMANAGER LLC biological products, (no diagnostic substances) | 997.0K | 1.57% | 1.57% | $1.35B | Nov 14, 2025 | ▲ 493.8K |
BLACKROCK, INC. biological products, (no diagnostic substances) | 968.7K | 1.52% | 1.52% | $1.31B | Nov 12, 2025 | ▲ 891.8K |
JANE STREET GROUP, LLC biological products, (no diagnostic substances) | 926.1K | 1.45% | 1.45% | $1.25B | Nov 14, 2025 | ▲ 912.9K |
RENAISSANCE TECHNOLOGIES LLC biological products, (no diagnostic substances) | 713.5K | 1.12% | 1.12% | $963.23M | Nov 13, 2025 | ▲ 617.1K |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 712.7K | 1.12% | 1.12% | $962.53M | Nov 12, 2025 | ▲ 344.0K |
HILTON CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 581.1K | 91.25% | 91.25% | $784.55M | Nov 12, 2025 | NEW |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
19
Increased
+5.42M shares20
New Positions
first time holders3
Decreased
−171.0K shares0
Sold Out
fully exitedNet shares change (top 50)
+5.25M
+5.42M / −171.0K
Net new holders
+36
20 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
CGTX insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
3
Buy transactions
5
Sell transactions
0.60
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Doyle John Brendan Chief Financial Officer | May 1, 2026 | Tax Withhold | 8,567 | $1.28 | $11.0K | 618.9K | Form 4 ↗ |
Doyle John Brendan Chief Financial Officer | Apr 16, 2026 | Purchase | 10,000 | $1.13 | $11.3K | 627.5K | Form 4 ↗ |
Ricciardi Lisa CEO & President | Apr 16, 2026 | Purchase | 9,175 | $1.10 | $10.1K | 1.72M | Form 4 ↗ |
Caggiano Anthony Chief Medical Officer | Apr 16, 2026 | Purchase | 10,000 | $1.11 | $11.1K | 874.9K | Form 4 ↗ |
Ricciardi Lisa CEO & President | Feb 15, 2026 | Tax Withhold | 5,850 | $1.12 | $6.6K | 1.71M | Form 4 ↗ |
Doyle John Brendan Chief Financial Officer | Feb 15, 2026 | Tax Withhold | 1,560 | $1.12 | $1.7K | 617.5K | Form 4 ↗ |
Caggiano Anthony Chief Medical Officer | Feb 15, 2026 | Tax Withhold | 4,680 | $1.12 | $5.2K | 864.9K | Form 4 ↗ |
Ricciardi Lisa CEO & President | Feb 3, 2026 | Award | 800,000 | — | — | 1.79M | Form 4 ↗ |
Ricciardi Lisa CEO & President | Feb 3, 2026 | Tax Withhold | 26,036 | $1.12 | $29.2K | 1.76M | Form 4 ↗ |
Ricciardi Lisa CEO & President | Feb 4, 2026 | Tax Withhold | 51,704 | $1.03 | $53.3K | 1.71M | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Cognition Therapeutics, Inc. (CGTX) is primarily owned by institutional investors, who hold approximately 28.9% of total shares outstanding. Company insiders own approximately 19.63%, while retail and public investors account for the remaining 51.46%.
The largest institutional shareholder of Cognition Therapeutics, Inc. is BIOS CAPITAL MANAGEMENT, LP, holding approximately 6.00 million shares — equal to 9.42% of outstanding shares — as of September 30, 2025.
A total of 69 institutional investors currently hold CGTX stock, with a combined institutional value of approximately $28,724,649 as of the most recent 13F filing period.
Frequently asked questions
CGTX ownershipCognition Therapeutics, Inc. (CGTX) is primarily owned by institutional investors, who hold approximately 28.9% of shares. The largest shareholder is BIOS CAPITAL MANAGEMENT, LP with a 9.42% stake. Company insiders hold 19.63%. Data sourced from SEC Form 13F as of September 30, 2025.